Our Mission
To improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches.
Polyneuropathy and CNS Angiopathy
Cardiomyopathy
Oculopathy
Our News
What is happening in our universe.
BSIM at the "3rd European ATTR Amyloidosis meeting for Patients and Doctors"
Trademark "BSIM Therapeutics" registered in the US
BSIM Therapeutics is awarded a European Patent
BSIM attended the XVIIth International Symposium on Amyloidosis
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more
